You just read:

Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Induces Alterations in Gene Expression and Demonstrates Potential Anticancer Activity in Non-Small Cell Lung Cancers, Malignant Pleural Mesothelioma and Melanomas, Cancers That Are Deficient in Key Metabolic Protein

News provided by

Polaris Group

Apr 29, 2014, 03:15 ET